 |
0 Diseases |  |
77 Trials |
|
77 Trials |  |
6639 News |  |
| «12...73747576777879808182838485» |
- ||||| furosemide / Generic mfg.
P3 data, Enrollment change: A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts (clinicaltrials.gov) - Aug 24, 2017
P3, N=480, Recruiting, Sponsor: Cutanea Life Sciences, Inc.
N=400 --> 480
- | furosemide / Generic mfg., nitroglycerin / Generic mfg.
New P2 trial: N-FURIOUS: Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial (clinicaltrials.gov) - Aug 23, 2017
P2, N=70, Not yet recruiting, Sponsor: Indiana University
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Aug 18, 2017
P1, N=41, Completed, Sponsor: Novo Nordisk A/S
N=400 --> 480 Active, not recruiting --> Completed
- | furosemide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive (clinicaltrials.gov) - Aug 11, 2017
P4, N=60, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Dec 2015 | Trial primary completion date: Jul 2017 --> Jan 2016
- | furosemide / Generic mfg.
Journal: A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. (Pubmed Central) - Aug 10, 2017
Moreover, a common variant in the multidrug resistance protein-4 coding gene (ABCC4, rs17268282) was associated with weight loss with furosemide use (P=0.0001). Our results suggest that both common and rare genetic variants modulate the response to a furosemide-based diuretic regimen in patients with decompensated HF.The Pharmacogenomics Journal advance online publication, 1 March 2016; doi:10.1038/tpj.2016.4.
- | Orfadin (nitisinone) / Astellas, SOBI
Trial completion: A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers (clinicaltrials.gov) - Aug 10, 2017
P1, N=36, Completed, Sponsor: Swedish Orphan Biovitrum
Our results suggest that both common and rare genetic variants modulate the response to a furosemide-based diuretic regimen in patients with decompensated HF.The Pharmacogenomics Journal advance online publication, 1 March 2016; doi:10.1038/tpj.2016.4. Active, not recruiting --> Completed
- | furosemide / Generic mfg.
Trial primary completion date: Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=270, Recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
Active, not recruiting --> Completed Trial primary completion date: Aug 2016 --> Aug 2017
- | furosemide / Generic mfg.
Trial primary completion date: SUBQ-Pilot: Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot (clinicaltrials.gov) - Jul 28, 2017
P1, N=40, Recruiting, Sponsor: Adrian Hernandez
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Jun 2017 --> Sep 2017
- | hydrochlorothiazide / Generic mfg., furosemide / Generic mfg., bumetanide / Generic mfg.
Enrollment open: POINCARE: Effects of Fluid Balance Control in Critically Ill Patients (clinicaltrials.gov) - Jul 27, 2017
P=N/A, N=1716, Recruiting, Sponsor: Central Hospital, Nancy, France
Trial primary completion date: Jun 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- | Journal: Efficacy and Safety of Tolvaptan in Patients Hospitalized with Acute Heart Failure. (Pubmed Central) - Jul 15, 2017
P3
In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a standardized furosemide regimen did not improve the number of responders at 24 h, despite greater weight loss and fluid loss. (Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).
- | cyclosporine / Generic mfg.
Journal: Calcineurin Inhibitor Cyclosporine A Activates Renal Na-(K)-Cl Cotransporters via Local and Systemic Mechanisms. (Pubmed Central) - Jul 15, 2017
Stimulation of cultured TAL cells with AVP agonist restored their responsiveness to CsA. Our results suggest that the direct epithelial effect of calcineurin inhibition is sufficient for the activation of NCC, whereas its effect on NKCC2 is more complex and requires concomitant stimulation by AVP.
- | Journal: Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. (Pubmed Central) - Jul 15, 2017
P3
Apparent subsequent differences in dyspnea warrant further exploration of the temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvaptan. (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CHF]; NCT01584557).
- | furosemide / Generic mfg.
Enrollment change, Trial termination: FFAKI: Forced Fluid Removal in High Risk Acute Kidney Injury (clinicaltrials.gov) - Jul 6, 2017
P4, N=21, Terminated, Sponsor: Nordsjaellands Hospital
(Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CHF]; NCT01584557). N=50 --> 21 | Recruiting --> Terminated; Very low recruitment rates
- | furosemide / Generic mfg.
New P3 trial: Role of Salbutamol and Furosemide in TTN (clinicaltrials.gov) - Jul 6, 2017
P3, N=100, Completed, Sponsor: Armed Forces Hospital, Pakistan
- | furosemide / Generic mfg.
Journal: Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. (Pubmed Central) - Jul 5, 2017
P3
N=50 --> 21 | Recruiting --> Terminated; Very low recruitment rates Combining 2 indicators of decongestion, hemoconcentration and diuretic response improves risk prediction for early rehospitalization after an admission for acute HF and may provide clinicians with an easily accessible tool to identify low-risk patients.
- | furosemide / Generic mfg.
Journal: Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. (Pubmed Central) - Jul 5, 2017
P=N/A
Hypochloremia is associated with neurohormonal activation and diuretic resistance with chloride depletion as a candidate mechanism. Sodium-free chloride supplementation was associated with increases in serum chloride and changes in several cardiorenal parameters.
- Orfadin (nitisinone) / Astellas, SOBI
Enrollment closed: A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers (clinicaltrials.gov) - Jul 2, 2017
P1, N=36, Active, not recruiting, Sponsor: Swedish Orphan Biovitrum
Sodium-free chloride supplementation was associated with increases in serum chloride and changes in several cardiorenal parameters. Enrolling by invitation --> Active, not recruiting
- | furosemide / Generic mfg.
Trial initiation date: Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide (clinicaltrials.gov) - Jun 27, 2017
P1, N=8, Not yet recruiting, Sponsor: Yale University
Enrolling by invitation --> Active, not recruiting Initiation date: Jun 2017 --> Sep 2017
- | Trial completion, Surgery: Early Diuresis Following Colorectal Surgery (clinicaltrials.gov) - Jun 27, 2017
P4, N=123, Completed, Sponsor: Mayo Clinic
Initiation date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed
- | furosemide / Generic mfg.
Trial completion, Trial primary completion date: Transfusion-Associated Circulatory Overload Best Eliminated With Lasix (clinicaltrials.gov) - Jun 26, 2017
P, N=80, Completed, Sponsor: Sunnybrook Health Sciences Centre
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Mar 2017
- | lercanidipine / Generic mfg., furosemide / Generic mfg., lisinopril / Generic mfg.
New P4 trial: Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) (clinicaltrials.gov) - Jun 22, 2017
P4, N=106, Recruiting, Sponsor: Hospital General Universitario Gregorio Marañon
- | furosemide / Generic mfg.
Trial completion, Enrollment change: Aerosol Inhalation Treatment for Dyspnea (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=24, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Mar 2017 Active, not recruiting --> Completed | N=15 --> 24
- | torasemide / Generic mfg.
Trial primary completion date: TORNADO: The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure (clinicaltrials.gov) - Jun 8, 2017
P4, N=100, Recruiting, Sponsor: Medical University of Warsaw
Active, not recruiting --> Completed | N=15 --> 24 Trial primary completion date: Mar 2016 --> Dec 2017
- Orfadin (nitisinone) / Astellas, SOBI
Enrollment status: A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers (clinicaltrials.gov) - May 31, 2017
P1, N=36, Enrolling by invitation, Sponsor: Swedish Orphan Biovitrum
Trial primary completion date: Mar 2016 --> Dec 2017 Recruiting --> Enrolling by invitation
- || Actimab-A (lintuzumab-Ac225) / Actinium
Trial primary completion date: Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov) - May 23, 2017
P1/2, N=72, Recruiting, Sponsor: Actinium Pharmaceuticals
Recruiting --> Enrolling by invitation Trial primary completion date: Jan 2017 --> May 2018
- | furosemide / Generic mfg.
Trial primary completion date: Prevention of Severe Postpartum Hypertension (clinicaltrials.gov) - May 9, 2017
P2, N=248, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jan 2017 --> May 2018 Trial primary completion date: Dec 2016 --> May 2018
- | furosemide / Generic mfg.
Trial initiation date: Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy (clinicaltrials.gov) - May 5, 2017
P4, N=144, Not yet recruiting, Sponsor: University of South Florida
Trial primary completion date: Dec 2016 --> May 2018 Initiation date: Feb 2017 --> Jun 2017
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Apr 28, 2017
P1, N=41, Active, not recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Feb 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- | tolvaptan / Generic mfg.
Trial primary completion date: AiDing Diuresis wIth Tolvaptan (ADD-IT) (clinicaltrials.gov) - Apr 14, 2017
P1, N=30, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Mar 2018
- | furosemide / Generic mfg.
Journal: Availability of Heart Failure Medications in Hospice Care. (Pubmed Central) - Apr 12, 2017
Trial primary completion date: Jan 2017 --> Mar 2018 This study highlights opportunities for practice guidelines that inform medical therapy for hospice patients with heart failure.
- | furosemide / Generic mfg.
Enrollment change, Trial termination: REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure (clinicaltrials.gov) - Apr 10, 2017
P4, N=10, Terminated, Sponsor: Niguarda Hospital
This study highlights opportunities for practice guidelines that inform medical therapy for hospice patients with heart failure. N=186 --> 10 | Suspended --> Terminated; insufficient enrollment
- | Orfadin (nitisinone) / Astellas, SOBI
New P1 trial: A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers (clinicaltrials.gov) - Apr 5, 2017
P1, N=36, Recruiting, Sponsor: Swedish Orphan Biovitrum
- | furosemide / Generic mfg.
New P1 trial: Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide (clinicaltrials.gov) - Mar 28, 2017
P1, N=8, Not yet recruiting, Sponsor: Yale University
- furosemide / Generic mfg.
Enrollment change, Trial withdrawal: DIVERSION-HF: A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen (clinicaltrials.gov) - Mar 24, 2017
P1/2, N=0, Withdrawn, Sponsor: Todd M Koelling, MD
N=186 --> 10 | Suspended --> Terminated; insufficient enrollment N=10 --> 0 | Recruiting --> Withdrawn
- | furosemide / Generic mfg.
Trial primary completion date: IRIHS-REA: Impact of Rational Control of Fluid Balance in the Intensive Care Unit (clinicaltrials.gov) - Mar 20, 2017
P3, N=172, Recruiting, Sponsor: Nantes University Hospital
N=10 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jul 2017 --> Jan 2019
- || furosemide / Generic mfg.
Trial primary completion date: Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov) - Mar 20, 2017
P2, N=120, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Jul 2017 --> Jan 2019 Trial primary completion date: Apr 2017 --> Jun 2019
- | furosemide / Generic mfg.
Journal: Efficacy of loop diuretics in the management of undocumented patients with end-stage renal disease. (Pubmed Central) - Mar 18, 2017
In our univariable analysis, patients on furosemide had 3.1 fewer ED visits on average compared with patients who are not on furosemide...These results suggest that loop diuretics may have an important role in undocumented patients with ESRD with residual renal function. Further study to develop practical approaches to the care of undocumented patients with ESRD is greatly needed.
- | hydrochlorothiazide / Generic mfg., furosemide / Generic mfg.
New trial: The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients (clinicaltrials.gov) - Mar 17, 2017
P=N/A, N=52, Recruiting, Sponsor: University of Sao Paulo General Hospital
- | furosemide / Generic mfg.
Enrollment closed, Trial primary completion date: ROPA-DOP: Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Mar 8, 2017
P4, N=120, Active, not recruiting, Sponsor: Johns Hopkins University
Further study to develop practical approaches to the care of undocumented patients with ESRD is greatly needed. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017
- | furosemide / Generic mfg.
Enrollment closed, Enrollment change: Aerosol Inhalation Treatment for Dyspnea - Patients (clinicaltrials.gov) - Mar 7, 2017
P1/2, N=25, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=55 --> 25
- | furosemide / Generic mfg.
New trial: FOSTIK: Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=50, Recruiting, Sponsor: King Chulalongkorn Memorial Hospital
- | furosemide / Generic mfg.
Enrollment open, Trial primary completion date: SUBQ-Pilot: Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot (clinicaltrials.gov) - Feb 27, 2017
P1, N=40, Recruiting, Sponsor: Adrian Hernandez
Recruiting --> Active, not recruiting | N=55 --> 25 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Jun 2017
- furosemide / Generic mfg.
Enrollment open: Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness (clinicaltrials.gov) - Feb 14, 2017
P1, N=30, Recruiting, Sponsor: McGill University
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- | metformin / Generic mfg., digoxin / Generic mfg., furosemide / Generic mfg.
Trial completion: Transporter Cocktail Mutual Interaction (clinicaltrials.gov) - Feb 8, 2017
P1, N=30, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Feb 3, 2017
P1, N=41, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- furosemide / Generic mfg.
Trial completion: ANSWER: Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis (clinicaltrials.gov) - Jan 23, 2017
P4, N=431, Completed, Sponsor: University of Bologna
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- furosemide / Generic mfg.
Trial primary completion date: Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=200, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2018
- |||||| furosemide / Generic mfg.
Enrollment open, P3 data: A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts (clinicaltrials.gov) - Jan 17, 2017
P3, N=400, Recruiting, Sponsor: Cutanea Life Sciences, Inc.
Trial primary completion date: Dec 2016 --> Dec 2018 Not yet recruiting --> Recruiting
- furosemide / Generic mfg.
Trial primary completion date: The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=200, Recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Jan 5, 2017
P1, N=41, Not yet recruiting, Sponsor: Novo Nordisk A/S